Fatigue during treatment for hepatitis C virus: Results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Scott, Jane ^a   Rosa, Kathleen ^b   Fu, Min ^c   Cerri, Karin ^d   Peeters, Monika ^c   Beumont, Maria ^c   Zeuzem, Stefan ^e   Evon, Donna M ^f   Gilles, Leen ^c  

^a Janssen Global Services LLC   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

EQ 5D; Fatigue; FSS; Hepatitis C virus; Patient reported outcomes; Peginterferon ; Ribavirin; Simeprevir; TMC435; Triple therapy

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SIMEPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPEAN QUALITY OF LIFE 5 DIMENSION QUESTIONNAIRE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN; SELF REPORT; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908412774     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-465     Document Type: Article

References (36)

1. World Health Organization 63rd World Health Assembly. Provisional agenda item 11_12; 25 March 2010. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf, World Health Organization.
2. Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn 2006, 2:121-131.
3. Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med 2008, 23:1959-1965. 10.1007/s11606-008-0790-y, 2596521, 18807097.
4. Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002, 47:2674-2681. 10.1023/A:1021040702370, 12498284.
5. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, Charlotte F, Piette JC, Moussalli J. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002, 9:295-303. 10.1046/j.1365-2893.2002.00364.x, 12081607.
6. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007, 52:2531-2539. 10.1007/s10620-006-9708-x, 17406828.
7. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 2012, 57:946-952. 10.1016/j.jhep.2012.06.030, 3477271, 22760009.
8. McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S. Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol 2002, 17:171-176. 10.1046/j.1440-1746.2002.02669.x, 11966947.
9. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004, 41:845-851. 10.1016/j.jhep.2004.07.022, 15519659.
10. Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J. Emerging evidence of hepatitis C virus neuroinvasion. AIDS 2005, 19(Suppl 3):S140-S144. 10.1097/01.aids.0000192083.41561.00, 16251811.
11. Seaman K, Paterson BL, Vallis M, Hirsch G, Peltekian KM. Future directions for investigation of fatigue in chronic hepatitis C viral infection. Chronic Illn 2009, 5:115-128. 10.1177/1742395309104476, 19474234.
12. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593. 10.1056/NEJMoa0808010, 19625712.
13. Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol 2012, 28:188-192. 10.1097/MOG.0b013e3283528e1e, 22476156.
14. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850. 10.1056/NEJMoa0807650, 19403903.
15. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012, 19(Suppl 2):1-26.
16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965. 10.1016/S0140-6736(01)06102-5, 11583749.
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047, 12324553.
18. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004, 40:675-681. 10.1016/j.jhep.2003.12.014, 15030985.
19. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012, 32(Suppl 1):88-102.
20. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217. 10.1056/NEJMoa1009482, 3153125, 21449784.
21. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206. 10.1056/NEJMoa1010494, 3766849, 21449783.
22. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013, 58:1918-1929. 10.1002/hep.26641, 23907700.
23. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hézode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros P, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M. Simeprevir (TMC435) in treatment-experienced HCV genotype 1 patients; the phase IIb, randomized. Controlled ASPIRE trial. Gastroenterology 2014, 146:430-441. 10.1053/j.gastro.2013.10.058, 24184810.
24. Kleinman L, Mannix S, Yuan Y, Kummer S, L'Italien G, Revicki D. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes 2012, 10:92. 10.1186/1477-7525-10-92, 3547737, 22871087.
25. Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J. Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes 2014, 12:90. 10.1186/1477-7525-12-90, 4094687, 24915781.
26. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123. 10.1001/archneur.1989.00520460115022, 2803071.
27. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343. 10.3109/07853890109002087, 11491192.
28. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord 2010, 25:805-822. 10.1002/mds.22989, 20461797.
29. Gencay-Can A, Can SS. Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int 2012, 32:27-31. 10.1007/s00296-010-1558-3, 20658235.
30. Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000, 9:499-508. 10.1023/A:1008960710415, 11190005.
31. Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003, 21:341-349. 10.2165/00019053-200321050-00005, 12627987.
32. Blackburn S, Humphrey L, McCool R, Panter C, Young V, Peterson S, Mitchell L, Machouf N, Scott J. Interviews with patients with chronic hepatitis C virus infection document unmet needs, content validity, and comprehension of PROs for Clinical Trials Poster presented at the 18th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 18-22, 2013, New Orleans, LA, USA.
33. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35:704-708. 10.1053/jhep.2002.31311, 11870387.
34. Versteegh MM, Rowen D, Brazier JE, Stolk EA. Mapping onto EQ-5D for patients in poor health. Health Qual Life Outcomes 2010, 8:141. 10.1186/1477-7525-8-141, 3002322, 21110838.
35. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide 2007, Berlin: Springer.
36. Scott J, Gilles L, Fu M, Peeters M, Brohan E, Amatya R, Jessner W, Beumont-Mauviel M. Adding simeprevir to pegylated interferon-α/ribavirin for HCV shortens time with patient-reported symptoms and impairment in quality of life: results from the simeprevir Phase III QUEST-1, QUEST-2 and PROMISE studies Poster presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 1-5, 2013, Washington, DC, USA.